Special Issue

Stem Cells and Cancer Therapeutics

Message from the Guest Editors

Stems cells are defined as cells with the ability to self-renew and to differentiate into multiple lineages. This definition applies to both physiologic and pathologic conditions. In the case of cancer, multiple experimental evidences support the existence of specific cell populations that are functionally identified for their capacity to initiate and propagate tumors. These cells have been classically called tumor initiating cells (TICs) or cancer stem cells (CSCs) and are supposed to possess stem cell-like properties, including long-term self-renewal, capacity of multi-lineage differentiation, increased resistance to therapy, and the ability to promote tumor relapse and metastasis. This special issue will focus on understanding the molecular mechanisms that control normal and cancer-related stemness and the tools that are currently available for studying them both in vitro and in vivo. In particular, we will pay attention in how TICs contribute to cancer progression and therapy resistance, and the possibility of specifically targeting TIC in anti-cancer therapies.

Guest Editors

Dr. Anna Vert

Stem Cells and Cancer Research Laboratory, CIBERONC. Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain

Dr. Lluis Espinosa

Stem Cells and Cancer Research Laboratory, CIBERONC. Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain

Deadline for manuscript submissions

closed (30 September 2018)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/10336

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).